Radiomics Model Based on Gadoxetic Acid Disodium-Enhanced MR Imaging to Predict Hepatocellular Carcinoma Recurrence After Curative Ablation

References

• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y31439937
   PubMed Web of Science ®Google Scholar
• Tang A, Hallouch O, Chernyak V, et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol. 2018;43(1):13–25. doi:10.1007/s00261-017-1209-1
   PubMed Web of Science ®Google Scholar
• Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on the status of cancer, 1975–2014, Featuring Survival. J Natl Cancer Inst. 2017;109(9). doi:10.1093/jnci/djx030
   Google Scholar
• Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–2166. doi:10.1111/liv.1281825752327
   PubMed Web of Science ®Google Scholar
• Yang JD, Mohamed EA, Aziz AO, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017;2(2):103–111. doi:10.1016/S2468-1253(16)30161-328403980
   PubMed Web of Science ®Google Scholar
• Zheng R, Qu C, Zhang S, et al. Liver cancer incidence and mortality in China: temporal trends and projections to 2030. Chin J Cancer Res. 2018;30(6):571–579. doi:10.21147/j.issn.1000-9604.2018.06.0130700925
   PubMed Web of Science ®Google Scholar
• Yin XY, Xie XY, Lu MD, et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer. 2009;115(9):1914–1923. doi:10.1002/cncr.2419619241423
   PubMed Web of Science ®Google Scholar
• Liang P, Dong B, Yu X, et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology. 2005;235(1):299–307. doi:10.1148/radiol.235103194415731369
   PubMed Web of Science ®Google Scholar
• Vietti Violi N, Duran R, Guiu B, et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled Phase 2 trial. Lancet Gastroenterol Hepatol. 2018;3(5):317–325. doi:10.1016/S2468-1253(18)30029-329503247
   PubMed Web of Science ®Google Scholar
• Glassberg MB, Ghosh S, Clymer JW, et al. Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. Onco Targets Ther. 2019;12:6407–6438. doi:10.2147/OTT.S20434031496742
   PubMed Web of Science ®Google Scholar
• Lee DH, Lee JM, Lee JY, et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology. 2014;270(3):900–909. doi:10.1148/radiol.1313094024475823
   PubMed Web of Science ®Google Scholar
• Groeschl RT, Wong RK, Quebbeman EJ, et al. Recurrence after microwave ablation of liver malignancies: a single institution experience. HPB (Oxford). 2013;15(5):365–371. doi:10.1111/j.1477-2574.2012.00585.x23458599
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M; American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022. doi:10.1002/hep.2419921374666
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943. doi:10.1016/j.jhep.2011.12.00122424438
   PubMed Web of Science ®Google Scholar
• Feng J, Zhu R, Feng D, et al. Prediction of Early Recurrence of Solitary Hepatocellular Carcinoma after Orthotopic Liver Transplantation. Sci Rep. 2019;9(1):15855. doi:10.1038/s41598-019-52427-831676847
   PubMed Web of Science ®Google Scholar
• Ng KK, Cheung T, Wong TCL, et al. Prediction Model for early intrahepatic recurrence after hepatectomy for patients with hepatocellular carcinoma: an implication for adjuvant treatment. J Am Coll Surg. 2018;227(4):e59. doi:10.1016/j.jamcollsurg.2018.08.152
   Web of Science ®Google Scholar
• Marsh JW, Dvorchik I, Subotin M, et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology. 1997;26(2):444–450. doi:10.1002/hep.5102602279252157
   PubMed Web of Science ®Google Scholar
• Al-Ameri AAM, Wei X, Wen X, et al. Systematic review: risk prediction models for recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int. 2020;33(7):697–712. doi:10.1111/tri.1358531985857
   PubMed Web of Science ®Google Scholar
• Roessler S, Jia HL, Budhu A, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70(24):10202–10212. doi:10.1158/0008-5472.CAN-10-260721159642
   PubMed Web of Science ®Google Scholar
• Zhao QJ, Zhang J, Xu L, et al. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma. World J Gastroenterol. 2018;24(30):3426–3439. doi:10.3748/wjg.v24.i30.342630122881
   PubMed Web of Science ®Google Scholar
• Zhang Z, Jiang H, Chen J, et al. Hepatocellular carcinoma: radiomics nomogram on gadoxetic acid-enhanced MR imaging for early postoperative recurrence prediction. Cancer Imaging. 2019;19(1):22. doi:10.1186/s40644-019-0209-531088553
   PubMed Web of Science ®Google Scholar
• Ma X, Wei J, Gu D, et al. Preoperative radiomics nomogram for microvascular invasion prediction in hepatocellular carcinoma using contrast-enhanced CT. Eur Radiol. 2019;29(7):3595–3605. doi:10.1007/s00330-018-5985-y30770969
   PubMed Web of Science ®Google Scholar
• Wakabayashi T, Ouhmich F, Gonzalez-Cabrera C, et al. Radiomics in hepatocellular carcinoma: a quantitative review. Hepatol Int. 2019;13(5):546–559. doi:10.1007/s12072-019-09973-031473947
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.2908628130846
   PubMed Web of Science ®Google Scholar
• Liu W, Zheng Y, Zou R, et al. Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation. BMC Cancer. 2018;18(1):1186. doi:10.1186/s12885-018-5069-z30497418
   PubMed Web of Science ®Google Scholar
• Wu M, Gao S, Song H, et al. Percutaneous thermal ablation combined with simultaneous transarterial chemoembolization for hepatocellular carcinoma </=5 cm. J Cancer Res Ther. 2019;15(4):766–772. doi:10.4103/jcrt.JCRT_250_1931436230
   PubMed Web of Science ®Google Scholar
• Galanakis N, Kehagias E, Matthaiou N, et al. Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review. Hepat Oncol. 2018;5(2):HEP07. doi:10.2217/hep-2018-000131293775
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43. doi:10.1016/S1470-2045(08)70284-519058754
   PubMed Web of Science ®Google Scholar
• Lin DC, Mayakonda A, Dinh HQ, et al. Genomic and epigenomic heterogeneity of hepatocellular carcinoma. Cancer Res. 2017;77(9):2255–2265. doi:10.1158/0008-5472.CAN-16-282228302680
   PubMed Web of Science ®Google Scholar
• Lu LC, Hsu CH, Hsu C, et al. Tumor heterogeneity in hepatocellular carcinoma: facing the challenges. Liver Cancer. 2016;5(2):128–138. doi:10.1159/00036775427386431
   PubMed Web of Science ®Google Scholar
• Kim HY, Lee DH, Lee JH, et al. Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. BMC Cancer. 2018;18(1):307. doi:10.1186/s12885-018-4211-229558905
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang HL, Liu QP, et al. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma. J Hepatol. 2019;70(6):1133–1144. doi:10.1016/j.jhep.2019.02.02330876945
   PubMed Web of Science ®Google Scholar
• Hui TCH, Chuah TK, Low HM, et al. Predicting early recurrence of hepatocellular carcinoma with texture analysis of preoperative MRI: a radiomics study. Clin Radiol. 2018;73(12):1056e11–1056e16. doi:10.1016/j.crad.2018.07.109
   Web of Science ®Google Scholar
• Yuan C, Wang Z, Gu D, et al. Prediction early recurrence of hepatocellular carcinoma eligible for curative ablation using a Radiomics nomogram. Cancer Imaging. 2019;19(1):21. doi:10.1186/s40644-019-0207-731027510
   PubMed Web of Science ®Google Scholar
• Vernuccio F, Cannella R, Meyer M, et al. LI-RADS: diagnostic performance of hepatobiliary phase hypointensity and major imaging features of LR-3 and LR-4 lesions measuring 10–19 mm with arterial phase hyperenhancement. AJR Am J Roentgenol. 2019;213(2):W57–w65. doi:10.2214/ajr.18.2097931039012
   PubMed Web of Science ®Google Scholar
• Rigatti SJ. Random Forest. J Insur Med. 2017;47(1):31–39. doi:10.17849/insm-47-01-31-39.128836909
   PubMedGoogle Scholar